Individuals Dispensed Buprenorphine in the United States Before and After Federal Policy Changes Aimed at Increasing Access.

Details

• Alternative Title:
  Journal of Addiction Medicine, 2025, v. 19, no. 5: Individuals Dispensed Buprenorphine in the United States Before and After Federal Policy Changes Aimed at Increasing Access.
• Journal Article:
  Journal of Addiction Medicine
• Personal Author:
  Guy, Gery P. ; Jones, Christopher M. ; Rikard, Michaela ; Strahan, Andrea E. ; Zhang, Kun ; Olsen, Yngvild
• Description:
  Buprenorphine can decrease opioid use disorder and mortality risk but remains underutilized. This study evaluates changes in monthly buprenorphine dispensing associated with federal policy changes in the United States from 2018 to 2023.
  
  This study used interrupted time series analysis comparing the monthly rate of patients dispensed buprenorphine after the implementation of telehealth flexibilities in March 2020, relaxation of training requirements in April 2021, and removal of waiver requirements in December 2022. Buprenorphine formulated for opioid use disorder was included from the IQVIA Total Patient Tracker.
  
  Before March 2020, the monthly rate of individuals dispensed buprenorphine was increasing. The rate of increase slowed after each policy change: -0.69 (95% CI=-1.00 to -0.39) after telehealth flexibilities were initiated, -0.60 (95% CI=-0.92 to -0.27) after relaxing training requirements, and -0.49 (95% CI=-0.73 to -0.24) after waiver elimination. After the elimination of the waiver, declines were observed across several specialty groups, including pain medicine, emergency medicine, and primary care, while the rate increased among addiction medicine specialists.
  
  After each policy change, the rate of individuals dispensed buprenorphine increased at a slower rate than before each policy change. These findings suggest that the removal of the waiver, while important, may not be sufficient on its own to meaningfully expand buprenorphine prescribing. Individual and systems-level strategies may be needed to fully optimize the impact of these policy changes focusing on reducing patient, clinician, and institutional stigma, addressing clinician barriers, implementing systems-level improvements, and strengthening payment policies that incentivize prescribing.
• Content Notes:
  Author manuscript
• Subjects:
  • Humans
  • Buprenorphine
  • Opioid-Related Disorders
  • Health Policy
  • Health Services Accessibility
  • Interrupted Time Series Analysis
  • Opiate Substitution Treatment
  • Telemedicine
  • Narcotic Antagonists
• Keywords:
  • treatment
  • buprenorphine
  • policy evaluation
• Source:
  Journal of Addiction Medicine, 2025, v. 19, no. 5
• DOI:
  https://doi.org/10.1097/ADM.0000000000001457
• ISSN:
  1932-0620 ; 1935-3227
• Pubmed ID:
  39969964
• Pubmed Central ID:
  PMC12353755
• Document Type:
  Text
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Genre:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  615-620 (11 pdf pages)
• Volume:
  19
• Issue:
  5
• Download URL:
  https://stacks.cdc.gov/view/cdc/261670/cdc_261670_DS1.pdf
• File Type:
  [PDF - 351.18 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:b1811ffe49107db0c61bfcf66377d4c783571075d25232f94701e9dbfce092d8abaa586e43bc86d4b865ff467fa9b867ca387d076f6a5df2c563f58434d44e40